BR112021023074A2 - Tratamento de disfunção sistólica e insuficiência cardíaca com fração de ejeção reduzida com o composto (r)-4-(l-(1-((3-(difluorometil)-l--1-metil-1h-pirazol-4-il)sulfonil)-l-1-fluoroetil)-n-(isoxazol-3-il)piperidina-l-1-carboxamida - Google Patents

Tratamento de disfunção sistólica e insuficiência cardíaca com fração de ejeção reduzida com o composto (r)-4-(l-(1-((3-(difluorometil)-l--1-metil-1h-pirazol-4-il)sulfonil)-l-1-fluoroetil)-n-(isoxazol-3-il)piperidina-l-1-carboxamida

Info

Publication number
BR112021023074A2
BR112021023074A2 BR112021023074A BR112021023074A BR112021023074A2 BR 112021023074 A2 BR112021023074 A2 BR 112021023074A2 BR 112021023074 A BR112021023074 A BR 112021023074A BR 112021023074 A BR112021023074 A BR 112021023074A BR 112021023074 A2 BR112021023074 A2 BR 112021023074A2
Authority
BR
Brazil
Prior art keywords
heart failure
compound
ejection fraction
isoxazol
fluoroethyl
Prior art date
Application number
BR112021023074A
Other languages
English (en)
Portuguese (pt)
Inventor
Chun Yang
Jean-Francois Tamby
Timothy Carlson
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of BR112021023074A2 publication Critical patent/BR112021023074A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112021023074A 2019-05-19 2020-05-18 Tratamento de disfunção sistólica e insuficiência cardíaca com fração de ejeção reduzida com o composto (r)-4-(l-(1-((3-(difluorometil)-l--1-metil-1h-pirazol-4-il)sulfonil)-l-1-fluoroetil)-n-(isoxazol-3-il)piperidina-l-1-carboxamida BR112021023074A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849936P 2019-05-19 2019-05-19
US201962852739P 2019-05-24 2019-05-24
PCT/US2020/033438 WO2020236736A1 (en) 2019-05-19 2020-05-18 Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Publications (1)

Publication Number Publication Date
BR112021023074A2 true BR112021023074A2 (pt) 2022-03-29

Family

ID=70978663

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023074A BR112021023074A2 (pt) 2019-05-19 2020-05-18 Tratamento de disfunção sistólica e insuficiência cardíaca com fração de ejeção reduzida com o composto (r)-4-(l-(1-((3-(difluorometil)-l--1-metil-1h-pirazol-4-il)sulfonil)-l-1-fluoroetil)-n-(isoxazol-3-il)piperidina-l-1-carboxamida

Country Status (16)

Country Link
US (2) US20220265629A1 (enExample)
EP (1) EP3972597A1 (enExample)
JP (2) JP2022535195A (enExample)
KR (1) KR20220009440A (enExample)
CN (1) CN114173782A (enExample)
AU (2) AU2020279710A1 (enExample)
BR (1) BR112021023074A2 (enExample)
CA (1) CA3138080A1 (enExample)
CL (1) CL2021003045A1 (enExample)
CO (1) CO2021015505A2 (enExample)
IL (1) IL288051A (enExample)
MX (2) MX2021014109A (enExample)
PE (1) PE20220426A1 (enExample)
SG (1) SG11202112723PA (enExample)
TW (2) TW202541801A (enExample)
WO (1) WO2020236736A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020315605A1 (en) 2019-07-16 2022-03-03 MyoKardia, Inc. Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide
KR102752382B1 (ko) * 2019-09-20 2025-01-09 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 안지오텐신 ii 수용체 길항제 대사물질 및 nep 억제제의 복합체의 심부전 치료에서의 용도
IL298885A (en) * 2020-06-15 2023-02-01 Myokardia Inc Treatment of atrial function
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure
US20250025460A1 (en) * 2021-12-02 2025-01-23 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
WO2005117882A2 (en) * 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
US8324178B2 (en) * 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
JP2014088342A (ja) * 2012-10-30 2014-05-15 Kowa Company Ltd ベンゾオキサジアゾール誘導体を有効成分とするｍｋ２阻害剤
PH12021553074A1 (en) * 2015-01-22 2023-03-06 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
LT3645002T (lt) * 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
WO2019006325A1 (en) * 2017-06-30 2019-01-03 Equalaire Systems, Inc. VENT CAP OF HUB CAP

Also Published As

Publication number Publication date
CL2021003045A1 (es) 2022-07-08
US20220265629A1 (en) 2022-08-25
MX2021014109A (es) 2021-12-10
WO2020236736A1 (en) 2020-11-26
TW202110449A (zh) 2021-03-16
CA3138080A1 (en) 2020-11-26
MX2025003918A (es) 2025-05-02
EP3972597A1 (en) 2022-03-30
SG11202112723PA (en) 2021-12-30
AU2025263744A1 (en) 2025-11-20
IL288051A (en) 2022-01-01
PE20220426A1 (es) 2022-03-29
TW202541801A (zh) 2025-11-01
AU2020279710A1 (en) 2021-12-23
JP2025106475A (ja) 2025-07-15
US20250241903A1 (en) 2025-07-31
CN114173782A (zh) 2022-03-11
KR20220009440A (ko) 2022-01-24
TWI874399B (zh) 2025-03-01
CO2021015505A2 (es) 2021-12-10
JP2022535195A (ja) 2022-08-05

Similar Documents

Publication Publication Date Title
MX2025003918A (es) Tratamiento de la disfuncion sistolica
CL2023002682A1 (es) Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos
PH12019502345A1 (en) Methods of treatment using a jak inhibitor compoud
JOP20190094A1 (ar) مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
MX2021005898A (es) Terapia de combinacion que incluye un inhibidor de krasg12c y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MX2022001328A (es) Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia.
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
CL2021002681A1 (es) Inhibidores de la dihidroorotato deshidrogenasa.
NI201200016A (es) Derivados de piridina y pirazina como moduladores de cinasa de proteína
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
JOP20210227A1 (ar) شكل بلوري من مونوهيدرات 1-(1-أوكسو-1، 2-داي هيدروأيزوكينولين-5-يل)-5-(تراي فلوروميثيل)-n-(2-(تراي فلوروميثيل)بيريدين-4-يل)-1h-بيرازول-4-كربوكساميد
BR112017015627A2 (pt) Compostos de piperidina ureia substituída com 4- metilsulfonila para o tratamento de cardiomiopatia dilatada (dcm)
BR112022000494A2 (pt) Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica
PH12022550083A1 (en) Cardiac sarcomere inhibitor oral formulations
CO2019012125A2 (es) Inhibidores ip6k
MX2021015853A (es) Analogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluor-met il)pirimidin-5-il]etil}benzamida.
PH12020550494A1 (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors
BR112021022712A2 (pt) Formas cristalinas de n-[4-(clorodifluorometóxi)fenil]-6-[(3r)-3-hidroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida
BR112013024368A2 (pt) combinações de composto ativo
MX2019002615A (es) Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion.
BRPI0918580B8 (pt) polimorfo cristalino b da n-(2-aminofenil)-4-[n-(piridina3-il)metóxi-carbonilaminometil]-benzamida, composição e combinação contendo o mesmo, uso e seu processo de produção
LT3886799T (lt) Kompozicija, skirta plaukų slinkimo gydymui
CO2017005990A2 (es) Combinaciones de compuestos activos que comprenden (a) una carboxamida de indanilo difluorometil-nicotínico de fórmula (i) y otro compuesto activo como fungicida (b)
MX2022015488A (es) Tratamiento para la disfuncion auricular.
DOP2022000099A (es) Antagonistas heterocíclicos de nmda